Software for self-monitoring of blood glucoseSeptember 14, 2018
DreaMed Advisor Pro, an artificial intelligence (AI)-based diabetes treatment decision support software has been granted De Novo approval by USFDA.
Advisor Pro is indicated to assist healthcare providers in the management of people with type 1 diabetes who use insulin pumps and continuous glucose monitoring (CGM).
DreaMed Advisor Pro is a cloud-based digital solution generating insulin delivery recommendations by analysing information from CGM, self-monitoring blood glucose (SMBG), and insulin pump data.
Applying event-driven adaptive learning, Advisor Pro refines its understanding for each individual and sends recommendations to the healthcare provider on how to optimize a patient’s insulin pump settings for basal rate, carbohydrate ratio (CR) and correction factor (CF).